TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 383287
Drug: High-dose methanol
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (2.0 mg)
Study: 383287
Drug: Low-dose methanol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (0.5 mg)
Study: 383287
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution placebo
Study: 26200180
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (insulin treatment if glucose >150 mg/dl)
Study: 21801540
Drug: Neostatin (lipid-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostatin (lipid-lowering drug)
Study: 19855033
Drug: Therapy status
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy status
Study: 9449397
Drug: Ang I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang I infusion
Study: 9449397
Drug: Ang II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang II infusion
Study: 7831698
Drug: Dextrorphan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrorphan (loading dose 60 to 150 mg, maintenance infusion maximum total dose 3310 mg)
Study: 7831698
Drug: Dextrorphan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrorphan (loading dose 145 to 260 mg, maintenance infusion 30 to 70 mg/h)
Study: 2194442
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids (high dose, short term)
Study: 25072647
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution
Study: 22947356
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg to 20 mg daily
Study: 22947356
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg to 40 mg daily
Study: 22947356
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg to 20 mg + Lisinopril 10 mg to 40 mg
Study: 16130176
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of nemifitide administered by standard needle/syringe
Study: 16130176
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of nemifitide administered by needle-free injection
Study: 16130176
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of nemifitide administered by needle-free injection
Study: 7072313
Drug: acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (400 mg/die)
Study: 7072313
Drug: diuretic mefrusid
Normalized name: mefruside
DrugBank: Mefruside (DB13405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretic mefrusid (25 mg/die)
Study: 7072313
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of acebutolol and mefrusid
Study: 30567753
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 or 840 mg daily) combined with high-dose methotrexate (HD-MTX) at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles) and rituximab.
Study: 27155289
Drug: Labels containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labels containing 'tsp' or 'teaspoon' units (alone or with 'mL')
Study: 27155289
Drug: Labels containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labels containing 'mL' only
Study: 27155289
Drug: Labels with
Normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labels with 'teaspoon' and 'mL'
Study: 27155289
Drug: Labels with
Normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labels with 'tsp' and 'mL'
Study: 16263089
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of delta-opioid receptors (DOR) and kappa-opioid receptors (KOR) in skin tissues
Study: 11867377
Drug: Physostigmine 2
Normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 2 mg IV
Study: 3904820
Drug: Acyclovir (excluding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (excluding prior antiviral treatment)
Study: 3904820
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside (excluding prior antiviral treatment)
Study: 16793623
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg estradiol benzoate injected intramuscularly
Study: 12657225
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) administered for 3 months
Study: 11080706
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 microg administered twice daily
Study: 11080706
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 800 microg administered twice daily
Study: 9475305
Drug: Subcutaneous jet-injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous jet-injection of recombinant human growth hormone (rhGH)
Study: 9475305
Drug: Conventional needle-injection
Normalized name: NEEDLES,INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional needle-injection of recombinant human growth hormone (rhGH)
Study: 7714412
Drug: Insulin eyedrops
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin eyedrops (50 microliters of sterile normal saline containing varying insulin concentrations)
Study: 7714412
Drug: Insulin eyedrops
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin eyedrops (100 U/ml in saline)
Study: 7714412
Drug: Insulin eyedrops
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin eyedrops
Study: 2455115
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg q.d. added to nifedipine 20 mg b.i.d.
Study: 2455115
Drug: Placebo q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo q.d. added to nifedipine 20 mg b.i.d.
Study: 27893474
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly squat exercises with whole-body vibration
Study: 26994090
Drug: Ceftolozane/tazobactam 1.5
Normalized name: ceftolozane/tazobactam 1.5 gram INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam 1.5 g every 8 hours for 7 days
Study: 26994090
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg once daily for 7 days
Study: 25450083
Drug: Probiotic VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic VSL#3 (9 × 10^11 bacteria) daily for 6 months
Study: 22956006
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg twice daily for 2 days)
Study: 20795923
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus inspiratory muscle training using a threshold device, with an initial load of 30% of their maximal inspiratory pressure, increased by 10% daily, administered for 5 min, twice a day, 7 days a week from the commencement of weaning until extubation.
Study: 18773749
Drug: Pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatments (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, fibric acid derivatives, insulin sensitizers, cannabinoid receptor type 1 blockers)
Study: 8008680
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Acebutolol therapy
Study: 26037324
Drug: Optimised usual
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised usual care (medication review by psychiatrist/geriatrician)
Study: 23814044
Drug: TCH (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH (six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year)
Study: 23814044
Drug: AC→TH (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC→TH (adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year)
Study: 19249413
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hydrochlorothiazide and Atenolol
Study: 15090706
Drug: Sauna therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sauna therapy (60 degrees C far infrared-ray dry sauna for 15 minutes followed by bed rest with a blanket for 30 minutes once a day for two weeks)
Study: 11146706
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alendronate and naproxen
Study: 9783096
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ECT
Study: 9783096
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ECT
Study: 2555187
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg.h-1)
Study: 25352655
Drug: SAXA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAXA (5 mg/day) plus DAPA (10 mg/day) on background MET (≥1,500 mg/day)
Study: 25352655
Drug: SAXA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAXA (5 mg/day) plus MET
Study: 25352655
Drug: DAPA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA (10 mg/day) plus MET
Study: 19669251
Drug: TACE +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE + thymalfasin (1.6 mg SC, 5 times weekly)
Study: 14970093
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily orally for 3 days followed by placebo for 4 days (3-day group, 93 patients)
Study: 14970093
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily orally for 7 days (7-day group, 90 patients)
Study: 12243820
Drug: Sucralfate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (3 g in 15 mL suspension) administered rectally
Study: 12243820
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same suspension without sucralfate) administered rectally
Study: 12243820
Drug: Rectal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pain of moderate or severe grade during RT
Study: 9678787
Drug: gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (600 mg b.d.)
Study: 9678787
Drug: bezafibrate mono
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate mono (400 mg daily)
Study: 2566637
Drug: Azidothymidine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azidothymidine therapy
Study: 25588784
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.2 to 0.9 mg twice daily)
Study: 24014208
Drug: Sesame lignans
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame lignans (50 mg, sesamin/episesamin=1/1)
Study: 11832182
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy after operation in group A
Study: 11832182
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B (no anticoagulation therapy)
Study: 9443614
Drug: FAN regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAN regimen: fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on days 1, 8, and 15 every 3 weeks.
Study: 9443614
Drug: SUPERFAN regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPERFAN regimen: fluorouracil 340 mg/m2 and folinic acid 200 mg/m2 on days 1-5, doxorubicin 40 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on day 1 and again on day 5 every 4 weeks.
Study: 3953330
Drug: Treatment prescribed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment prescribed to 52 incontinent residents
Study: 30869167
Drug: Perampanel 2-12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 2-12 mg/day
Study: 29516701
Drug: Intradermal needle‐embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needle‐embedding therapy (once every other day for 20 days)
Study: 29516701
Drug: Conventional medicines,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicines, neuromuscular electrical stimulation of the bilateral midlines of the neck and swallowing function training
Study: 12243439
Drug: Sweep gas
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweep gas flow at 1.60 l/min/m2 (Group 2)
Study: 12243439
Drug: Sweep gas
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweep gas flow at 2.0 l/min/m2 (Group 3)
Study: 12243439
Drug: Sweep gas
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweep gas flow at 1.35 l/min/m2 (Group 1)
Study: 2152844
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d) and cholecalciferol (25 micrograms/d) supplementation
Study: 417361
Drug: Piracetam 9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 9.6 g/day
Study: 27651506
Drug: Crushed intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed intranasal Morphine ARER
Study: 27651506
Drug: Intact Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact Morphine ARER
Study: 25546166
Drug: Canagliflozin/metformin (150/1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fed state
Study: 25546166
Drug: Canagliflozin/metformin (150/1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fasted state
Study: 21237212
Drug: Acipimox (Aci)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (Aci) administered 1h before exercise (45 min, 2 W/kg of lean body mass)
Study: 21237212
Drug: Acipimox (Aci)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (Aci) administered 1h before exercise
Study: 19217443
Drug: Hyperinsulinemic-euglycemic (H-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic-euglycemic (H-E) clamp with porcine or human insulin (40 mU/[m(2) min])
Study: 19217443
Drug: Porcine vs
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine vs human insulin
Study: 15784036
Drug: Octreotide 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 300 mug, b.i.d. plus midodrine 7.5 mg, t.i.d.
Study: 11915786
Drug: ephedrine 6
Normalized name: pseudoephedrine 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 6 mg (Group E‐6)
Study: 11915786
Drug: ephedrine 12
Normalized name: ePHEDrine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 12 mg (Group E‐12)
Study: 7722706
Drug: Atole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (high protein and energy supplement)
Study: 1779513
Drug: Corinfar (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corinfar (20 mg)
Study: 1779513
Drug: Hypothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothiazide (50 mg)
Study: 1779513
Drug: Anapriline (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anapriline (80 mg)
Study: 7240596
Drug: Urushiol oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urushiol oil injections
Study: 28864284
Drug: Caffeine-containing analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing analgesics (300 mg acetaminophen and 20 mg caffeine)
Study: 28864284
Drug: Codeine-containing analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine-containing analgesics (300 mg acetaminophen and 20 mg codeine)
Study: 25261399
Drug: 0.4 %
Normalized name: oxygen 20.4 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 % stannous fluoride gel and a crème containing 10 % CPP‐ACP applied three times daily and fluoride gel once daily
Study: 25261399
Drug: Similar crème
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar crème without CPP‐ACP applied three times daily and fluoride gel once daily
Study: 24293993
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1800 mg
Study: 9673532
Drug: L-carnitine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine treatment (20 mg/kg intravenously at the end of each hemodialysis session)
Study: 8033496
Drug: DuP 128
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 128 (900 mg per day)
Study: 8033496
Drug: DuP 128
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 128 (1800 mg per day)
Study: 8033496
Drug: DuP 128
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 128 (3600 mg per day)
Study: 8033496
Drug: Neomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (1 gm twice a day)
Study: 1092282
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride with marital therapy
Study: 1092282
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with marital therapy
Study: 30741469
Drug: Maxillary implant
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary implant overdentures on solitary attachments (group I)
Study: 30741469
Drug: Maxillary implant
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary implant overdentures on bars (group II)
Study: 28011037
Drug: Lumacaftor 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 400 mg every 12 h / Ivacaftor 250 mg every 12 h
Study: 28011037
Drug: Lumacaftor 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 600 mg once daily / Ivacaftor 250 mg every 12 h
Study: 21654350
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 4 times daily
Study: 17178957
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g IV)
Study: 17178957
Drug: Ampicillin-sulbactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (3 g IV)
Study: 12753318
Drug: Pamidronate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (0.5 mg/kg) given at the time of transplantation and 1 month later
Study: 10618584
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor alone (captopril)
Study: 6631616
Drug: self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-administered questionnaire
Study: 17697141
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of aspirin
Study: 8393509
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of oral azathioprine and methotrexate and high-dose intravenous methotrexate with leucovorin rescue
Study: 3034018
Drug: Hydrochlorothiazide (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (concomitant treatment for nonresponders)
Study: 15662290
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg t.i.d.
Study: 10233186
Drug: bosentan 700
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bosentan 700 mg
Study: 10233186
Drug: misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 400 mg
Study: 8904256
Drug: High-dose vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vecuronium (0.3 mg kg‐1)
Study: 29555790
Drug: Chlorothiazide 500
Normalized name: chlorothiazide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 500 mg
Study: 19663893
Drug: Continued low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continued low-dose steroids
Study: 19663893
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal and continued low-dose steroids
Study: 17008577
Drug: Staged care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staged care intervention participants received computerized motivational feedback at baseline and at 3, 6, and 12 months, and were offered a 6-session psychological counseling and pharmacological cessation treatment program.
Study: 17008577
Drug: Brief contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief contact control participants received a self-help guide and referral list of local smoking-treatment providers.
Study: 14574348
Drug: almond‐LCD (84
Approvals — FDA: no, EMA: no, PMDA: no
Description: almond‐LCD (84 g/day of almonds, 39% total fat, 25% MUFA, 32% carbohydrate)
Study: 14574348
Drug: almond‐LCD (84
Approvals — FDA: no, EMA: no, PMDA: no
Description: almond‐LCD (84 g/day of almonds)